You are here

Kategorie: Medicine Wellness Health

Medicine Wellness Health 

Asahi Kasei’s novel forward osmosis–membrane distillation system installed at Peptistar’s API manufacturing facility

PR-Gateway,

TOKYO – June 25, 2026 – Japanese pharmaceutical contract development and manufacturing organization (CDMO) Peptistar has integrated Asahi Kasei’s novel forward osmosis–membrane distillation (FO–MD) system into its facility for trial production of active pharmaceutical ingredients (APIs). Asahi Kasei, a diversified global company, announced in 2018 the development of a system that dehydrates and concentrates liquids without the application of heat or pressure. This reduces the number of freeze-drying batches and the amount of time required for freeze-drying, thereby shortening API manufacturing time. Peptistar has begun operation of the novel system…

Mehr...

Die 10 besten Nasenkorrektur- (Rhinoplastik-) Chirurgen in der Türkei

Kris

Die Türkei zählt heute zu den weltweit führenden Destinationen im Bereich Medizintourismus und ästhetische Medizin. Insbesondere in den letzten Jahren ist die Zahl internationaler Patienten, die für eine Nasenkorrektur in die Türkei reisen, deutlich gestiegen. Ein wesentlicher Grund dafür sind die zunehmend auf sozialen Medien präsentierten Ergebnisse mit einem natürlichen Erscheinungsbild. Nach Ansicht von Experten liegt das Geheimnis einer erfolgreichen Rhinoplastik nicht allein darin, die Nase zu verkleinern oder anzuheben. Entscheidend ist vielmehr, ein Ergebnis zu erzielen, das zur Gesichtsstruktur, zur Atemfunktion und zur individuellen Mimik des Patienten passt. Die…

Mehr...
Medicine Wellness Health 

Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute

PR-Gateway

A Major Milestone for More Efficient and Safer Cancer Treatments TOKYO – May 27, 2026 – Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute. This modality enables precise control over the drug-to-antibody ratio and attachment site of single- and dual-payload ADCs, representing a major breakthrough toward more effective and safer use in a broad range of therapies. ADCs are an advanced form of targeted biologics treatment that combines the precision of an antibody with the potency of a…

Mehr...
Medicine Wellness Health 

Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy

PR-Gateway

-Aicuris“s three antiviral assets complement Asahi Kasei“s therapy portfolio -Aicuris revenue expected to reach $500 million by 2030 -FDA has granted Priority Review for the redeliver New Drug Application. Prescription Drug User Fee Act (PDUFA) target date is Q4 2026 TOKYO – April 20, 2026 – Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company. This closing marks a key step in accelerating the company“s efforts to build a global specialty pharmaceutical platform by expanding further…

Mehr...
Medicine Wellness Health 

Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases

PR-Gateway

TOKYO – April 20, 2026 – Asahi Kasei, a diversified global company, today announced the initiation of a Phase I clinical trial for AK1940, a novel peptide-based investigational compound developed to address significant unmet medical needs in patients with autoimmune diseases. The trial is being conducted by Asahi Kasei Therapeutics Corp., its pharmaceutical subsidiary based in Japan. AK1940 was discovered through a joint research initiative with PeptiDream Inc. and represents an important facet of Asahi Kasei“s strategy to strengthen its pharmaceutical development pipeline and drive long-term growth. Preclinical studies have…

Mehr...
Medicine Wellness Health 

New hope for more than 5000 ureteral stent patients daily

PR-Gateway, , , ,

Better quality of life despite ureteral stents: New technology offers potential to reduce pain, infections, and emergency treatments for more than 5,500 patients daily Baiersdorf, Germany, March 17, 2026 – UroNova GmbH today announced the results from its CLEANUS clinical study. The data impressively demonstrate that the innovative coating for ureteral stents effectively combats side effects previously considered unavoidable. The newly developed, non-pharmacological coating for ureteral stents virtually eliminates severe encrustation while significantly reducing patient pain and infection rates. – Growing clinical need: The increasing number of patients with kidney…

Mehr...
Medicine Wellness Health 

Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds

PR-Gateway

TOKYO – February 25, 2026 – Asahi Kasei Pharma announced that it has strengthened its drug discovery pipeline through an exclusive global license agreement regarding novel lead compounds for a single target with Alchemedicine, a company specializing in the discovery of small molecule drugs. The license agreement was executed on February 3, 2026, and follows the companies“ recent announcement on advancing AK1960 to a Phase I study. Under the agreement, Asahi Kasei Pharma obtained exclusive worldwide rights to research, develop, manufacture, and commercialize the compounds, which are currently at the…

Mehr...
Medicine Wellness Health 

Asahi Kasei Pharma and Alchemedicine advance a novel therapeutic candidate into Phase I study

PR-Gateway

TOKYO – February 18, 2026 – Asahi Kasei Pharma, a global provider of healthcare and pharmaceutical solutions, in collaboration with Alchemedicine, has announced that its novel Endothelin A (ETA) receptor antagonist AK1960 has advanced to a Phase I clinical study following a successful preclinical phase. AK1960 is expected to be used in the treatment of various refractory diseases-medical conditions resistant to standard therapies. The initiation of a Phase I study is considered a significant step toward growing Asahi Kasei“s healthcare impact. AK1960 is a small molecule with a new core…

Mehr...
Medicine Wellness Health 

Asahi Kasei Microdevices Showcases AgeTech and PetTech Solutions Combining Privacy and Convenience at CES® 2026

PR-Gateway

TOKYO – November 13, 2025 – Asahi Kasei Microdevices Corporation (AKM) will showcase its latest sensing technologies for the growing AgeTech and PetTech markets at CES® 2026. The demonstrations, featuring technologies such as millimeter-wave radar and energy-harvesting innovations, will be presented in the Digital Health section of the Venetian Expo at booth 54829. With aging populations driving increased demand for safety and wellness solutions, AKM is focusing on technologies that address real-world health and caregiving challenges. According to the U.S. Centers for Disease Control and Prevention (CDC), one in four…

Mehr...
Medicine Wellness Health 

Asahi Kasei Elevates Critical Care Solutions with FDA Approval of ZOLL“s Zenix Monitor/Defibrillator

PR-Gateway

Chelmsford, MA; Novi, MI; Düsseldorf, Germany; and Tokyo, Japan – October 9, 2025 – Asahi Kasei, a global provider of healthcare technology and pharmaceutical solutions, has advanced its suite of critical care products through premarket approval by the U.S. Food and Drug Administration (FDA) for ZOLL“s Zenix® monitor/defibrillator. The Zenix device is the culmination of years of user feedback and is ZOLL“s most clinically advanced, user-friendly professional monitor/defibrillator. Asahi Kasei“s critical care lineup under ZOLL® is a key growth driver supporting long-term corporate development. The Zenix monitor/defibrillator is designed for…

Mehr...